Other Information.
−Removed: Insider Trading Arrangements and Policies
−Removed: During the quarter ended March 31, 2024, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulations S-K.
−Removed: Press Release
−Removed: On May 14, 2024, we issued a press release announcing our financial results for the quarter ended March 31, 2024.
+Added: On August 13, 2024, we issued a press release announcing our financial results for the quarter ended June 30, 2024.
A copy of the news release is attached to this Quarterly Report as Exhibit 99.1.
The press release is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, unless such subsequent filing specifically references the press release.
−Removed: License and Supply Agreement, dated March 15, 2024, between Fennec Pharmaceuticals, Inc.
−Removed: and Norgine Pharma UK Limited.
Certification of Chief Executive Officer of the Company in accordance with Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
1 unchanged sentence
Certification of Chief Executive Officer and Chief Financial Officer of the Company in accordance with Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith).
−Removed: Press Release for Quarter Ended March 31, 2024 (filed herewith).
+Added: Press Release for Quarter Ended June 30, 2024 (filed herewith).
Inline XBRL Instance Document
6 unchanged sentences
information contained in Exhibits 101)
−Removed: In accordance with Item 601(b)(10)(iv) of Regulation S-K, certain provisions and terms of this exhibit have been redacted.
−Removed: Fennec will provide an unredacted copy of the exhibit on a supplemental basis to the SEC or its staff upon request.
Pursuant to requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Fennec Pharmaceuticals Inc.
+Added: August 13, 2024
/s/ Rostislav Raykov
2 unchanged sentences
(principal executive officer)
+Added: August 13, 2024
/s/ Robert Andrade
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.